{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:05:28Z","timestamp":1767665128329},"reference-count":34,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blonanserin is an atypical antipsychotic drug with high affinity and selective antagonism for dopamine D<jats:sub>2<\/jats:sub> and D<jats:sub>3<\/jats:sub> and serotonin 5\u2010HT<jats:sub>2A<\/jats:sub> receptors. Blonanserin transdermal patch is the first transdermal formulation developed for the treatment of schizophrenia. The purpose of this population pharmacokinetic (PPK) analysis was to evaluate the characteristics of blonanserin pharmacokinetics after transdermal patch application, to estimate the daily fluctuation in blonanserin plasma concentration, and to evaluate the impact of patch application noncompliance to support usage in clinical settings. A total of 3747 plasma blonanserin concentrations from 9 clinical studies (93 healthy volunteers and 348 patients with schizophrenia) were used in the PPK analysis. The plasma concentration was predicted using the final PPK model, and dopamine D<jats:sub>2<\/jats:sub> receptor occupancy was estimated on the basis of the results of a separately reported positron emission tomography study. A 2\u2010compartment, parallel zero\u2010order absorption with a lag time and first\u2010order elimination model was developed to describe the pharmacokinetics of blonanserin, including the change in absorption rate during patch application. The maximum\/minimum ratio of plasma concentration was estimated as 1.10 at steady state, indicating minimal fluctuation. In the case of failure to remove the previous patch or a missing application, the increase or decrease in plasma concentration and dopamine D<jats:sub>2<\/jats:sub> receptor occupancy was &lt;20%. These results indicated that the plasma blonanserin concentration and dopamine D<jats:sub>2<\/jats:sub> receptor occupancy were stable after blonanserin transdermal patch application, which may lead to improved tolerability during the treatment of patients with schizophrenia.<\/jats:p>","DOI":"10.1002\/jcph.1835","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T16:00:56Z","timestamp":1613664056000},"page":"1069-1080","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D<sub>2<\/sub> Receptor Occupancy in Clinical Settings"],"prefix":"10.1002","volume":"61","author":[{"given":"Atsushi","family":"Kitamura","sequence":"first","affiliation":[{"name":"Clinical Research Drug Development Division Sumitomo Dainippon Pharma Co., Ltd.  Konohana\u2010ku Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Takagaki","sequence":"additional","affiliation":[{"name":"Clinical Research Drug Development Division Sumitomo Dainippon Pharma Co., Ltd.  Konohana\u2010ku Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Clinical Research Drug Development Division Sumitomo Dainippon Pharma Co., Ltd.  Konohana\u2010ku Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Tomita","sequence":"additional","affiliation":[{"name":"Clinical Research Drug Development Division Sumitomo Dainippon Pharma Co., Ltd.  Konohana\u2010ku Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Nishibe","sequence":"additional","affiliation":[{"name":"Clinical Research Drug Development Division Sumitomo Dainippon Pharma Co., Ltd.  Chuo\u2010ku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Kakuyama","sequence":"additional","affiliation":[{"name":"Clinical Research Drug Development Division Sumitomo Dainippon Pharma Co., Ltd.  Chuo\u2010ku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"729","article-title":"What is \u201cadherence\u201d in the treatment of schizophrenia?","volume":"11","author":"Koyama T","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_2_10_3_1","first-page":"1633","article-title":"Adherence in schizophrenia","volume":"11","author":"Sawada N","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10865-007-9147-y"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923070-00006"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12057"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2020.03.006"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11202620-000000000-00000"},{"key":"e_1_2_10_9_1","first-page":"2142","article-title":"Current status and problems of drug therapy and future development, as seen by a pharmacist\u2014does the selection of the dosage form improve patient adherence?","volume":"10","author":"Yoshio T","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_2_10_10_1","article-title":"Striatal dopamine D2 receptor occupancy induced by daily application of blonanserin transdermal patches: phase 2 study in Japanese patients with schizophrenia","author":"Nishibe H","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.055"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00692-6"},{"key":"e_1_2_10_13_1","first-page":"759","volume-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications","author":"Gabrielsson J","year":"2007"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/81.2.152"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.008"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04221.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011942213508"},{"issue":"7","key":"e_1_2_10_18_1","first-page":"17","article-title":"Comparison of the peak\u2010to\u2010trough fluctuation in plasma concentration of long\u2010acting injectable antipsychotics and their oral equivalents","volume":"9","author":"Sheehan JJ","year":"2012","journal-title":"Innov Clin Neurosci"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502001-00004"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182979a0a"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08841"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.05.007"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410060-00005"},{"key":"e_1_2_10_25_1","unstructured":"RISPERDAL\u00aeCONSTA\u00ae[prescribing information].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021346s063lbl.pdfUpdated January 2020. Accessed September 30 2020."},{"key":"e_1_2_10_26_1","unstructured":"ABILIFY MAINTENA\u00ae[prescribing information].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202971s013lbl.pdfUpdated January 2020. Accessed September 30 2020."},{"key":"e_1_2_10_27_1","unstructured":"INVEGA SUSTENNA\u00ae[prescribing information].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022264s029lbl.pdf. Updated January 2019. Accessed September 30 2020."},{"key":"e_1_2_10_28_1","unstructured":"ZYPREXA RELPREVV (olanzapine) for extended release injectable suspension [prescribing information].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022173s034lbl.pdfUpdated October 2019. Accessed September 30 2020."},{"key":"e_1_2_10_29_1","unstructured":"CLOPIXOL\u00aeDEPOT [prescribing information].https:\/\/pdf.hres.ca\/dpd_pm\/00024771.PDF. Updated April 2014. Accessed September 27 2020."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1379412"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S53795"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312458311"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.7.717"},{"key":"e_1_2_10_34_1","first-page":"678","article-title":"Introduction of shared decision making (SDM) in psychiatry","volume":"14","author":"Johannes H","year":"2011","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200043335531"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1835","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T01:24:18Z","timestamp":1693358658000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/jcph.1835"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1835","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"2020-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}